

















Chemcon Speciality Chemicals Limited Investor Presentation – May 2024

Safe Harbor



This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Chemcon Speciality Chemicals Limited (the "Company")**, have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.

Q4 & FY24 Performance Highlights



Q4 & FY24 Performance Highlights



"We reported total revenue of Rs 267 crore in FY24, reflecting a 12% decrease compared to the previous year. This decline was driven by soft demand of key products amid global economic uncertainty and lower realizations, which adversely impacted our annual performance. Organic chemicals such as HMDS, CMIC, and Bromobenzene have seen slow uptake from pharmaceutical and agrochemical clients. On a positive note, demand for our recently launched organic chemical has improved year-over-year, and we expect reasonable growth in the next financial year. Our inorganic chemicals business experienced mixed results due to unstable demand, supply chain disruptions, and deferred dispatches to clients. We anticipate demand and price across the products to normalize in H2FY25.


As part of our strategic plan, we are introducing new products to our portfolio. These products are currently in the trial phase and are expected to become operational at our upcoming facilities, P-10 and P-11. The expansion of these units has been deferred to H2FY25. We will continue to make prudent capital allocations to expand our product line, as we have done in previous years. Based on our ongoing client engagements, we anticipate stable growth in the upcoming fiscal year and remain optimistic about our long-term growth prospects."

Mr. Kamal Aggarwal,

Chairman & Managing Director


Financial Highlights





Financial Highlights





Profit & Loss Statement



Particulars (Rs. Crs)	Q4 FY24	Q4 FY23	Y-o-Y	FY24	FY23	Y-o-Y
Revenue from Operations	59.6	79.1	-24.6%	267.1	302.9	-11.8%
Cost of Goods Sold	41.3	53.6		188.9	175.7	
Employee Cost	4.8	5.0		18.0	20.5	
Other Expenses	9.1	6.4		33.3	35.9	
EBITDA	4.4	14.1	-68.8%	26.9	70.7	-62.0%
EBITDA Margin	7.4%	17.8%		10.1%	23.3%	
Other Income	3.3	2.9		13.2	13.3	
Depreciation	2.5	2.3		10.3	8.4	
EBIT	5.2	14.7		29.8	75.6	
Finance Cost	1.0	0.5		3.5	1.5	
Profit before Tax	4.2	14.2		26.3	74.2	
Тах	1.3	3.7		7.1	19.0	
PAT	2.9	10.5	-72.3%	19.2	55.1	-65.2%
PAT Margin %	4.9%	13.2%		7.2%	18.2%	
Basic EPS	0.79	2.86		5.24	15.04	

Balance Sheet



ASSETS (Rs. Crs)	Mar-24	Mar-23
Non-Current Assets		
a) Property, Plant And Equipment	146.5	141.4
b) Capital Work in Progress	42.4	13.6
c) Right Of Use Asset	0.0	0.0
d) Intangible Assets	0.0	0.0
e) Other Financial Assets	0.9	84.0
f) Other Non-Current Assets	2.3	3.0
Sub-Total - Non-Current Assets	192.1	242.0
Current Assets		
a) Inventories	61.6	79.0
b) Financial Assets		
i)Trade Receivables	81.9	67.6
ii) Cash And Cash Equivalents	7.1	44.4
iii) Bank Balances	163.5	86.4
iv) Other Financial Assets	9.6	4.3
c) Other Current Assets	21.8	24.4
d) Current tax assets	7.7	5.1
Sub-Total - Current Assets	353.2	311.4
Total - Assets	545.2	553.4

EQUITY AND LIABILITIES	Mar-24	Mar-23
EQUITY AND LIABILITIES		
Equity		
a) Equity Share Capital	36.6	36.6
b) Other Equity	439.8	420.7
Total Equity	476.4	457.4
Liabilities		
Non-Current Liabilities		
a) Financial Liabilities		
i) Borrowings	0.4	0.7
ii) Lease Liabilities	0.0	0.0
iii) Other financial liabilities	0.0	0.8
b) Non current Provisions	0.3	0.1
c) Deferred Tax Liabilities (Net)	4.4	3.1
Sub-Total - Non-Current Liabilities	5.1	4.7
Current Liabilities		
a) Financial Liabilities		
i) Borrowing	42.3	63.2
ii) Trade Payables	12.1	21.4
iii) Other Financial Liabilities	5.5	4.1
iv) Lease Liabilities	0.0	0.0
b) Other Current Liabilities	3.6	2.4
c) Short Term Provisions	0.2	0.0
d) Current tax Liabilities	0.0	0.0
Sub-Total - Current Liabilities	63.7	91.3
Total - Equity And Liabilities	545.2	553.4

Cash Flow Statement



Particulars (Rs. Crs.)	Mar-24	Mar-23
Net Profit Before Tax	26.3	74.2
Adjustments for: Non Cash Items / Other Investment or Financial Items	1.4	-0.8
Operating profit before working capital changes	27.7	73.3
Changes in working capital	-6.7	-38.5
Cash generated from Operations	21.0	34.9
Direct taxes paid (net of refund)	-9.0	-22.1
Net Cash from Operating Activities	12.0	12.7
Net Cash from Investing Activities	-24.6	-16.3
Net Cash from Financing Activities	-24.8	12.0
Net Decrease in Cash and Cash equivalents	-37.4	8.4
Add: Cash & Cash equivalents at the beginning of the period	44.4	36.0
Cash & Cash equivalents at the end of the period	7.1	44.4

Company Overview



Company Snapshot



Incorporated in 1988

Manufacturer of Speciality Chemicals



Business Verticals: Organic Chemicals and Inorganic Chemicals

Manufacturing Facilities near Manjusar, Vadodara, Gujarat

9 Operational Plants, 6 Owned Warehouses













Only Manufacturer of HMDS in India



3rd Largest Manufacturer of HMDS Worldwide



Largest Manufacturer of CMIC worldwide



Only Manufacturer of Zinc Bromide in India



Largest Manufacturer of Calcium Bromide in India

Evolution



FY89

» Company was incorporated as Gujarat Quinone Private Limited

FY95-98

- » First sale of few chemical products
- Pyridine Hydrobromide
- Para Nitro Benzyl Bromide
- Methyl Iodide
- GA-1

FY01-03

- » Commenced HMDS Business in 2001
- Discontinued few products due to lower demand

FY05

- » First export shipment of HMDS
- » Amalgamation of Chemcon Engineers Private Limited with Gujarat Quinone Private Limited; name changed to "Chemcon Speciality Chemicals Private Limited"

FY14

» First sale of CMIC

FY15-16

- » First sale of Calcium Bromide (Solution)
- » First sale of Zinc Bromide (Solution



FY17

- First sale of Calcium Bromide (Powder)
- » First sale of Sodium Bromide Solution

- -

FY18

- » Increase in annual installed production capacity for
- **CMIC** from 600 to 1.200 MTPA:
- Oilwell Completion
 Chemicals from 7,200
 to 14,400 MTPA



FY19

» Increase in annual installed production capacity for CMIC from 1,200 MTPA to 1,800 MTPA



FY20

» Increase in HMDS Capacity by commissioning of plant P7



FY21

» Plant P2 commissioned with a capacity to manufacture ancillary product of HMDS

FY22 -23

- » Increase in CMIC & TMCS Capacity by commissioning of plant P8
- » Increase in bromobenzene capacity by commissioning plant P-9

Global Market Presence







Key Countries

» United States of

» Japan

America

» United Arab

» Italy

Emirates

» South Korea

» Russia

» Germany

» Spain

» People's Republic of » Thailand

China

» Malaysia

Over Two Decades of

Manufacturing

Experience in Chemicals • Exports



Well Equipped to Seize Upcoming Opportunities

Entry Barriers



Complex Chemistry

» The involvement of complex chemistry in the manufacture of the Products, which is difficult to commercialize on a large scale

Long Gestation Period

» Customer acquisition involves a long gestation period, resulting in a very few players being involved in manufacturing of the products

Entry Barriers

Regulatory Norms

» To comply with all regulatory norms and filings with various agencies

Stringent Impurity Measure

Our processes and products are subject to, and measured against, high quality standards and stringent impurity specifications

Technical Know-how

» Handling chemicals requires a high degree of technical skill and expertise and operations involving such hazardous chemicals ought to be undertaken only by personnel who are well trained to handle such chemicals

High Replacement Cost

» Any change in the vendor of the product may require significant time and cost for the customer

Key Long-Term Relationships



Organic Chemicals

Inorganic Chemicals

















Shree Radha CC Gran Limited **Overseas**

Liability Company

Longstanding Clients



Strong Base



New Product Development



New Customer Reach

Top 5 customers contribute ~40% **Top 10 customers** contribute ~55%

Few customers age more than 2 decades with us


Major customers have been with us for more than 5 years

Well equipped to retain market presence

Leading to increase in new product base and reach out to new customers

Moving up the Value Chain





Key Certifications



Key Certificates







R&D

In-house laboratory to test

- » Raw materials procured
- » New Products & Innovation
- » Final products testing at the various stages of the manufacturing process
- » Well equipped with new instruments & machinery



Environment

Complying All Environment Laws

- » The Environment (Protection) Act, 1986
- » Water Prevention and Control of Pollution Act
- » Air Prevention and Control of Pollution Act, 1981
- » We are a zero-discharge company



Product Overview



Product Portfolio



Organic Chemicals

CMIC

HMDS

- HMDS, an organosilicon compound, is a reagent and a precursor to bases that are popular in organic synthesis and organometallic chemistry
- HMDS is widely used in the pharmaceutical industry as a silylating agent in the process of manufacture of pharmaceutical drugs of the Penicillin group

- CMIC is an antiviral drug intermediate product, which is a key intermediate for anti-AIDS and anti-hepatitis B drug Tenofovir
- The downstream product of CMIC, Tenofovir is a nucleotide antiviral drug developed by Gilead Corporation of the United States.

Bromobenzene

Bromobenzene, is a clear, colourless or pale-yellow liquid. It is manufactured through bromination of benzene in presence of iron and has form of heavy, mobile, colorless liquid having a pungent odor.

Inorganic Chemicals

Bromides

- Oilwell Completion Chemicals are used to complete the well and is normally a salty solution made up of chlorides or bromides
- Company manufacture a range of inorganic bromides, namely: Calcium Bromide (solution and powder), Zinc Bromide (solution) & Sodium Bromide (solution and powder)

End User Industry

Key Products


Pharmaceuticals & Others


Pharmaceuticals

Agrochemicals

Oil Drilling & Fluids

Business Performance (Rs in cr)





Manufacturing Facilities



Sr No	Product categories	Key Products	Installed Capacity (MTPA)
1		HMDS, CMIC, Bromobenzene and other ancillary products	10,800
2	Organic Chemicals	Proposed P-10 Capacity	H2FY25e
3		Proposed P-11 Capacity	H2FY25e
4	Inorganic Chemicals	Range of Inorganic Bromides	15,000

Plant

atory

Located at Manjusar near Vadodara, Gujarat





Growth Drivers



Capacity Expansion

We plan to add additional manufacturing capacity P10 unit and P11 unit by H2FY25. These additional capacity will manufacture organic chemicals

Exploring New Applications

» Plan to expand the new products to have diversified product portfolio with diversified client base

Import Substitution

» Aims to capitalize on the potential growth of Organic Chemicals in India and to substitute imports

Cost Efficiencies

» Ongoing improvement in cost-efficiencies in the production process through Process re-engineering for efficient raw material consumption and through economies of scale

Way Forward



Moderate Growth in

Organic Chemicals



Healthy Growth in

Inorganic Chemicals



Exploring Opportunities in

New Products



Leading to Long Term Sustainable Growth


New Products, New Clients, New Applications, New Opportunities

Financial Highlights



Financial Trends






Key Ratios

. . .





Thank You





Chemcon Speciality Chemicals Ltd.

CIN - L24231GJ1988PLC011652

Mr. Rajesh Gandhi - CFO

Email – <u>rajesh@cscpl.com</u>

www.cscpl.com

$SGA^{\underline{\tt Strategic\ Growth\ Advisors}}$

Strategic Growth Advisors Pvt. Ltd.

CIN - U74140MH2010PTC204285

Mr. Shrikant Sangani / Ms. Shaily Patwa

Email - shrikant.sangani@sgapl.net/ shrikant.sangani@sgapl.net/ shrikant.sangani@sgapl.net/

+91 9619595686 /+91 9819494608

www.sgapl.net

